• 30% YoY growth in revenue to $15.7 million
• Record test volumes in Australia, with MetaXplore sales up 136%
• Successful UK market expansion, with MetaXplore now 66% of all gastrointestinal tests

Microba Life Sciences Ltd has reported a transformative year of growth and strategic accomplishments in its FY2025 annual results. The company delivered 30% year-over-year revenue growth, reaching $15.7 million, while discontinuing legacy products to focus on its core diagnostic offerings. In Australia, MetaXplore test sales grew 136% to 11,065 tests, with an annualized run-rate of 13,800 tests by year-end. MetaPanel also made progress in early market development, with over 850 tests sold. The successful integration of the Invivo Healthcare acquisition in the UK unlocked rapid growth, with MetaXplore achieving full market access and representing around 66% of all gastrointestinal tests sold by Microba's UK business by the end of the year. Microba also released landmark clinical utility study results, showing that its tests can identify actionable insights for 71.4% of patients and lead to improved outcomes for two-thirds of patients. The company streamlined operations, completing the migration away from legacy offerings to focus on its core diagnostic products. While the bottom line remained in loss for the year, Microba ended FY2025 with a robust cash position of $11.74 million, which was further strengthened by a $14.5 million capital raise. Looking ahead, Microba is focused on continuing to drive adoption of MetaXplore and MetaPanel, achieving regional break-even objectives, and maintaining disciplined financial management to rapidly drive towards self-sustaining growth.

Microba expects FY2026 to build on FY2025's momentum, with each quarter surpassing the last as the company deepens its clinician network and rolls out planned product enhancements. The company is targeting regional break-even in Australia and the UK during FY2026.

Microba remains focused on accelerating the transition of its core testing products, MetaXplore and MetaPanel, at the forefront of the new $25 billion microbiome diagnostics market opportunity. The company is confident that the groundwork laid in FY2025 in market expansion, product validation, and operational focus positions it to capitalize on this significant growth opportunity.